Endo Has Left The Chat

Three guys with Reddit accounts rank GLP-1 agonists by vibe while the only board-certified member of the group quietly mutes notifications.

Filed under Tirzepatide ·Mazdutide ·Survodutide · #glp-1 ·#discord ·#cope

Active Compounds

Tirzepatide · Dual GIP/GLP-1 Receptor Agonist

A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.

Mazdutide · Incretin Mimetic

The world's first approved dual GLP-1/glucagon receptor agonist, developed by Innovent Biologics (China). Approved in China for obesity and type 2 diabetes. Phase 3 trials showed up to 20.1% weight loss.

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

RX: Tirzepatide · Mazdutide · Survodutide
Dosage: one (1) tier list
Half-life: until the endo unmutes
Source: manual
Tags: glp-1 , discord , cope
Stamped: 2026-05-13 · Cycle 019
Lot #: LOT-20260513T18:48:18.361Z